Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Cyclospora parasite illnesses have affected 28 NC counties, sickened more than 200 people
Recommended
UNC has a new chancellor. Why interim Lee Roberts got the permanent job.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(OP:
LOBEF
)
0.0150
+0.0016 (+11.94%)
Streaming Delayed Price
Updated: 1:23 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about LOBEF
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.
Via
Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
World's Largest Psychedelics Conference Boasts 12K Attendees
Via
Benzinga
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
June 28, 2023
Lobe Sciences Ltd. (OTCQB: LOBEF), a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has commenced its Phase 1 clinical...
Via
Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...
Via
Benzinga
Mass-Scale Psilocin Clinical Supplies Are Ready For Upcoming Trials
October 14, 2022
Canadian biotech company Lobe Sciences Ltd.
Via
Benzinga
New Share Consolidation of Lobe Sciences Ltd., Here's What Changes
June 08, 2022
Lobe Sciences Ltd.
Via
Benzinga
Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up
April 20, 2023
Orphan and rare diseases drug company Lobe Sciences Ltd. (OTCQB: LOBEF) is set to acquire Altemia & Company LLC.
Via
Benzinga
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
February 28, 2023
As early as the 1950s, scientists were researching the possible therapeutic benefits of psychedelics such as LSD and psilocybin mushrooms.
Via
Benzinga
Chronic Cluster Headaches, Next Target For This Non-Hallucinogenic Psychedelic
January 27, 2023
Lobe Sciences (OTCQB: LOBEF), the psychedelics company performing drug R&D with sub-hallucinatory doses of psychedelics has signed a research agreement with headache medicine specialist Dr. Lauren R.
Via
Benzinga
Psychedelics Funding At Its Best: $1.5 M Destined To Psilocybin Clinical Trials In Australia
September 01, 2022
Psychedelics biopharma company Lobe Sciences Ltd.
Via
Benzinga
This Psychedelic Company Just Signed An Exclusive Deal For Psilocin Clinical Trials In Australia
August 10, 2022
Life sciences company Lobe Sciences Ltd.
Via
Benzinga
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
July 19, 2022
Mydecine (OTC: MYCOF) and Lobe Sciences (OTCQB: LOBEF), two companies in the psychedelics space, have filed patent applications.
Via
Benzinga
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
June 15, 2022
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider.
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.